DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
ASLAN001 is an investigational drug.
There have been 11 clinical trials for ASLAN001. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2017.
The most common disease conditions in clinical trials are Biliary Tract Neoplasms, Stomach Neoplasms, and Neoplasms. The leading clinical trial sponsors are Aslan Pharmaceuticals, National University Hospital, Singapore, and National Medical Research Council (NMRC), Singapore.
There are one hundred and twenty-one US patents protecting this investigational drug and seven hundred and ninety-nine international patents.
Recent Clinical Trials for ASLAN001
|Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer||Aslan Pharmaceuticals||Phase 2|
|Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)||Aslan Pharmaceuticals||Phase 2/Phase 3|
|Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer||Aslan Pharmaceuticals||Phase 2/Phase 3|
Top disease conditions for ASLAN001
Top clinical trial sponsors for ASLAN001
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ASLAN001||Get Started Free||Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer||Capella Therapeutics, Inc. (San Diego, CA)||Get Started Free|
|ASLAN001||Get Started Free||Methods for the treatment of HER2 amplified cancer||Pharmacyclics LLC (Sunnyvale, CA)||Get Started Free|
|ASLAN001||Get Started Free||Compositions of obeticholic acid and methods of use||Intercept Pharmaceuticals, Inc. (New York, NY)||Get Started Free|
|ASLAN001||Get Started Free||Androgen receptor antagonists||The Regents of the University of California (Oakland, CA)||Get Started Free|
|ASLAN001||Get Started Free||Gene fusions and gene variants associated with cancer||LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)||Get Started Free|
|ASLAN001||Get Started Free||Anti-neurotensin antibodies and uses thereof||INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Universite Paris Descartes (Paris, FR)||Get Started Free|
|ASLAN001||Get Started Free||mTORC1 inhibitors||The Regents of the University of California (Oakland, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ASLAN001||Australia||AU2015231202||2034-03-20||Get Started Free|
|ASLAN001||Canada||CA2943220||2034-03-20||Get Started Free|
|ASLAN001||China||CN106536506||2034-03-20||Get Started Free|
|ASLAN001||European Patent Office||EP3119762||2034-03-20||Get Started Free|
|ASLAN001||Israel||IL247852||2034-03-20||Get Started Free|
|ASLAN001||Japan||JP2017512833||2034-03-20||Get Started Free|
|ASLAN001||Japan||JP2020007327||2034-03-20||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|